| Literature DB >> 35546162 |
Pei-Ying Chen1, Eugene Yu-Chuan Kang1,2, Kuan-Jen Chen1,2, Xiao Chun Ling1, Yin-Hsi Chang1, Nan-Kai Wang3, Laura Liu1,2, Yen-Po Chen2,4, Yih-Shiou Hwang1,2,3,5, Chi-Chun Lai1,6, Wei-Chi Wu7,8.
Abstract
There has been limited research regarding the status of foveal hypoplasia and the characteristics of the optical components of the eye in patients with familial exudative vitreoretinopathy (FEVR) and retinopathy of prematurity (ROP). In this retrospective cohort study, patients were classified into five groups: patients with stage 1 and 2 FEVR (FEVR group), patients with ROP who received treatment (treated ROP group), patients with ROP who did not receive treatment (untreated ROP group), patients without ROP who had been born preterm (preterm group), and healthy patients who had been born at term (full-term group). Visual acuity, refractive error, characteristics of the optical components, and features of the fovea were compared. In total, 179 eyes from 100 patients were included. Patients in the FEVR group had the highest degrees of myopia (p < 0.001). The axial length of patients in the FEVR group was significantly longer than that of patients in the treated and untreated ROP, preterm, and full-term groups (p < 0.001, p < 0.001, p = 0.001, and p = 0.003, respectively). Patients in the FEVR group had a higher proportion of grade 4 foveal hypoplasia and thinner foveae than those in the other groups (p < 0.001). Patients with FEVR had significantly greater myopic change than patients with ROP; the significantly longer axial length of the FEVR group might be the reason for the greater myopic change and lesser macular thickness. Patients in the FEVR group had more foveal hypoplasia than those in the other groups.Entities:
Mesh:
Year: 2022 PMID: 35546162 PMCID: PMC9095679 DOI: 10.1038/s41598-022-11455-7
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Patient demographics in the different study groups.
| FEVR | Treated ROP | Untreated ROP | Preterm | Full-term | ||
|---|---|---|---|---|---|---|
| No. of eyes (patients) | 34 (24) | 36 (20) | 32 (16) | 38 (20) | 39 (20) | |
| Age, yrs | 7.9 ± 3.9 | 7.4 ± 2.4 | 5.8 ± 1.3 | 7.1 ± 2.4 | 7.0 ± 2.7 | 0.25 |
| GA, wks | 38.2 ± 2.1 | 26.3 ± 2.3 | 27.8 ± 2.2 | 32.3 ± 3.0 | 38.8 ± 1.2 | < 0.001 |
| BW, g | 3074.1 ± 469.8 | 819.6 ± 203.6 | 916.4 ± 355.3 | 1600.1 ± 501.8 | 3036.6 ± 477.7 | < 0.001 |
| 0.38 | ||||||
| Male | 14 (58%) | 9 (45%) | 8 (50%) | 12 (60%) | 15 (75%) | |
| Female | 10 (42%) | 11 (55%) | 8 (50%) | 8 (40%) | 5 (25%) | |
| Laser | 20 (16) | 12 (7) | – | – | – | |
| IVI of anti-VEGF | – | 20 (11) | – | – | – | |
| Laser + IVI of anti-VEGF | – | 4 (2) | – | – | – | |
FEVR: familial exudative vitreoretinopathy; ROP: retinopathy of prematurity; GA: gestational age; BW: birth weight; IVI: intravitreal injection; VEGF: vascular endothelial growth factor.
Refractive error and optical-component features of patients.
| FEVR (1) | Treated ROP (2) | Untreated ROP (3) | Preterm (4) | Full-term (5) | Post hoca | ||
|---|---|---|---|---|---|---|---|
| Uncorrected logMAR VA | 1.2 ± 0.7 | 0.5 ± 0.5 | 0.2 ± 0.3 | 0.1 ± 0.2 | 0.2 ± 0.3 | < 0.001 | 1-2, 1-3, 1-4, 1-5, 2-4, 2-5 |
| Corrected logMAR VA | 0.5 ± 0.7 | 0.07 ± 0.2 | 0.02 ± 0.1 | 0.03 ± 0.1 | 0.03 ± 0.1 | < 0.001 | 1-2, 1-3, 1-4, 1-5 |
| Spherical power, D | − 6.2 ± 6.8 | − 1.4 ± 4.6 | 0.3 ± 1.4 | 0.4 ± 2.9 | 0.5 ± 0.9 | < 0.001 | 1-2, 1-3, 1-4, 1-5 |
| Cylindrical power, D | − 1.6 ± 1.3 | − 1.6 ± 1.6 | − 1.1 ± 1.6 | − 0.5 ± 0.5 | − 0.4 ± 0.7 | < 0.001 | 1-4, 1-5, 2-4, 2-5, 3-5 |
| Spherical equivalent, D | − 7.0 ± 7.0 | − 2.2 ± 4.8 | − 0.3 ± 1.6 | 0.2 ± 2.9 | 0.3 ± 0.9 | < 0.001 | 1-2, 1-3, 1-4, 1-5, 2-5 |
| K1 | 42.7 ± 1.9 | 44.2 ± 1.9 | 43.8 ± 1.9 | 43.0 ± 2.2 | 42.3 ± 1.6 | 0.006 | 1-2, 2-5, 3-5 |
| K2 | 44.7 ± 1.9 | 46.1 ± 2.1 | 45.6 ± 1.7 | 44.0 ± 2.4 | 43.7 ± 1.7 | < 0.001 | 2-4, 2-5, 3-4, 3-5 |
| K1-K2 average | 43.7 ± 1.8 | 45.2 ± 1.9 | 44.7 ± 1.7 | 43.5 ± 2.3 | 43.0 ± 1.6 | 0.001 | 2-4, 2-5, 3-5 |
| Anterior chamber depth, mm | 3.2 ± 0.4 | 3.2 ± 0.3 | 3.1 ± 0.4 | 3.2 ± 0.4 | 3.3 ± 0.2 | 0.067 | |
| Axial length, mm | 24.4 ± 2.6 | 22.4 ± 1.0 | 22.3 ± 1.1 | 22.7 ± 1.0 | 22.9 ± 0.7 | 0.001 | 1-2, 1-3, 1-4, 1-5 |
FEVR: familial exudative vitreoretinopathy; ROP: retinopathy of prematurity; VA: visual acuity; D: diopters.
aIntergroup comparisons were made using the post hoc comparisons from significant generalized estimating equations; the pairs of groups listed (e.g., 1-2) are significantly different. Pairs not shown are not significantly different.
Foveal hypoplasia in each group.
| Group | FEVR (1) | Treated ROP (2) | Untreated ROP (3) | Preterm (4) | Full-term (5) |
|---|---|---|---|---|---|
| Absence of foveal hypoplasia | 14 (41.2%) | 20 (55.6%) | 27 (84.4%) | 38 (100%) | 39 (100%) |
| Grade 1 (absence of the extrusion of plexiform layers) | 9 (26.5%) | 14 (38.9%) | 5 (15.6%) | 0 (0%) | 0 (0%) |
| Grade 2 (absence of the fovea pit) | 1 (2.9%) | 1 (2.8%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Grade 3 (absence of OS lengthening) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Grade 4 (absence of ONL widening) | 8 (23.5%) | 1(2.8%) | 0 (0%) | 0 (0%) | 0 (0%) |
| No OCT dataa | 2 | 0 | 0 | 0 | 0 |
FEVR: familial exudative vitreoretinopathy; ROP: retinopathy of prematurity; OS: outer segment; ONL: outer nuclear layer; OCT: optical coherence tomography.
p value: < 0.001.
aOCT scans that could not be judged by ophthalmologists.
Macular structures in each group.
| FEVR (1) | Treated ROP (2) | Untreated ROP (3) | Preterm (4) | Full-term (5) | Post hoca | ||
|---|---|---|---|---|---|---|---|
| Volume, mm3 | 7.6 ± 1.2 | 8. 9 ± 0.7 | 8.4 ± 0.5 | 8.8 ± 0.8 | 8.8 ± 0.5 | < 0.001 | 1-2, 1-3, 1-4, 1-5, 2-3, 3-5 |
| Foveal thickness, µm | 250.9 ± 40.6 | 291.0 ± 34.8 | 281.4 ± 25.1 | 276.9 ± 41.7 | 257.9 ± 46.4 | 0.001 | 1-2, 1-3, 1-4, 2-5, 3-5 |
| 284.3 ± 43.5 | 337.8 ± 36.2 | 323.2 ± 17.0 | 335.1 ± 23.5 | 337.2 ± 19.1 | < 0.001 | 1-2, 1-3, 1-4, 1-5, 2-3, 3-4, 3-5 | |
| Temporal | 275.2 ± 50.6 | 325.1 ± 38.0 | 318.7 ± 30.3 | 325.3 ± 23.6 | 327.9 ± 19.4 | < 0.001 | 1-2, 1-3, 1-4, 1-5 |
| Nasal | 292.8 ± 42.7 | 339.9 ± 38.2 | 328.7 ± 19.2 | 337.9 ± 19.1 | 342.6 ± 23.4 | < 0.001 | 1-2, 1-3, 1-4, 1-5, 3-5 |
| Superior | 285.3 ± 48.4 | 347.0 ± 43.1 | 325.5 ± 11.6 | 341.5 ± 39.7 | 339.8 ± 12.4 | < 0.001 | 1-2, 1-3, 1-4, 1-5, 2-3, 3-4, 3-5 |
| Inferior | 284.0 ± 40.9 | 338.9 ± 59.9 | 319.8 ± 21.7 | 335.7 ± 36.9 | 338.4 ± 41.4 | < 0.001 | 1-2, 1-3, 1-4, 1-5, 3-5 |
| 262.2 ± 45.3 | 306.1 ± 26.3 | 294.3 ± 21.7 | 306.4 ± 30.9 | 307.3 ± 16.9 | < 0.001 | 1-2, 1-3, 1-4, 1-5, 3-5 | |
| Temporal | 248.6 ± 47.6 | 300.5 ± 31.4 | 279.7 ± 26.9 | 294.0 ± 37.3 | 297.4 ± 17.8 | < 0.001 | 1-2, 1-3, 1-4, 1-5, 2-3, 3-5 |
| Nasal | 285.2 ± 51.0 | 321.3 ± 30.9 | 308.5 ± 20.3 | 317.5 ± 19.8 | 324.5 ± 23.5 | 0.007 | 1-2, 1-4, 1-5, 3-5 |
| Superior | 260.0 ± 51.1 | 309.4 ± 30.7 | 302.8 ± 34.7 | 321.7 ± 76.9 | 307.7 ± 15.2 | < 0.001 | 1-2, 1-3, 1-4, 1-5 |
| Inferior | 255.0 ± 42.6 | 293.4 ± 27.2 | 285.9 ± 31.9 | 292.5 ± 26.8 | 299.5 ± 28.1 | < 0.001 | 1-2, 1-3, 1-4, 1-5 |
FEVR: familial exudative vitreoretinopathy; ROP: retinopathy of prematurity.
aIntergroup comparisons were made using the post hoc comparisons from significant generalized estimating equations; the pairs of groups listed (e.g., 1-2) are significantly different. Pairs not shown are not significantly different.
Parameters of eyes with familial exudative vitreoretinopathy.
| Stage 1 | Stage 2 | ||
|---|---|---|---|
| Uncorrected logMAR VA | 1.3 ± 0.7 | 1.2 ± 0.8 | 0.741 |
| Corrected logMAR VA | 0.7 ± 0.7 | 0.3 ± 0.4 | 0.140 |
| Spherical power, D | − 7.0 ± 6.9 | − 4.4 ± 6.7 | 0.315 |
| Cylindrical power, D | − 1.6 ± 1.4 | − 1.5 ± 0.9 | 0.866 |
| Spherical equivalent, D | − 7.8 ± 7.2 | − 5.1 ± 6.7 | 0.322 |
| K1 | 42.9 ± 2.1 | 42.4 ± 1.4 | 0.525 |
| K2 | 44.9 ± 2.0 | 44.4 ± 1.6 | 0.443 |
| K1-K2 average | 43.9 ± 1.9 | 43.4 ± 1.5 | 0.467 |
| Anterior chamber depth, mm | 3.1 ± 0.4 | 3.6 ± 0.4 | 0.002 |
| Axial length, mm | 24.1 ± 2.1 | 25.2 ± 3.6 | 0.394 |
| Macular structures in OCT | |||
| Absence of foveal hypoplasia | 10 (45.5%) | 4 (40.0%) | 0.881 |
| Grade 1 (absence of the extrusion of plexiform layers) | 6 (27.3%) | 3 (30.0%) | |
| Grade 2 (absence of the fovea pit) | 0 (0%) | 0 (0%) | |
| Grade 3 (absence of OS lengthening) | 1 (4.5%) | 0 (0%) | |
| Grade 4 (absence of ONL widening) | 5 (22.7%) | 3 (30.0%) | |
| Macular volume, mm3 | 7.3 ± 0.9 | 8.0 ± 1.6 | 0.082 |
| Foveal thickness, µm | 239.9 ± 40.8 | 274.3 ± 30.3 | 0.004 |
| Parafoveal thickness, µm | 277.6 ± 42.9 | 300.3 ± 43.2 | 0.055 |
| Perifoveal thickness, µm | 254.2 ± 30.0 | 281.4 ± 68.6 | 0.088 |
VA: visual acuity; D: diopters; OCT: optical coherence tomography; OS: outer segment; ONL: outer nuclear layer.
Figure 1Comparison of optical-component characteristics and fovea status between patients with familial exudative vitreoretinopathy (FEVR) and patients with retinopathy of prematurity (ROP) who had received treatment.
Figure 2Comparison of optical-component characteristics and fovea status between patients with retinopathy of prematurity (ROP) who had not received treatment and full-term patients.